Eli Lilly has agreed to acquire AtaiBeckley in a transaction valued at up to $3.8B, expanding its neuroscience portfolio with late‑stage therapies for treatment‑resistant depression and other mental health disorders. The deal includes approximately $2.8B in upfront cash consideration, with the remaining value tied to contingent milestone payments linked to the progress of key pipeline programs.
Under the agreement, AtaiBeckley shareholders will receive a cash payment for each share at closing and may earn additional payments through contingent value rights based on specified development, regulatory, and commercialization milestones. The acquisition is intended to add several psychedelic‑based and other mechanistically novel candidates to Lilly’s pipeline, reflecting growing industry interest in new approaches for difficult‑to‑treat psychiatric conditions.
AtaiBeckley’s most advanced asset is BPL‑003, a Phase 3–ready intranasal formulation derived from the DMT class, in development for treatment‑resistant depression. Earlier‑stage programs include additional candidates targeting depression and anxiety disorders using rapid‑acting mechanisms aimed at synaptic plasticity and circuit modulation.
Lilly said the acquisition aligns with its strategy to pursue high‑impact medicines in areas of substantial unmet need, with mental health identified as a priority alongside its established presence in metabolic disease and oncology. The company plans to integrate AtaiBeckley’s R&D operations into its neuroscience organization while continuing ongoing clinical trials.
The transaction is expected to close later this year, subject to AtaiBeckley shareholder approval and customary regulatory clearances.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!